This inventor holds 1 USPTO granted patent. Top assignee: The Nemours Foundation. Active years: 1999.
Company Filing History:
Years Active: 1999
Title: Innovating Diagnosis: Mena Scavina's Breakthrough in Spinal Muscular Atrophy
Introduction: Mena Scavina, an accomplished inventor based in Philadelphia, PA, has made significant contributions to the field of genetic diagnostics. With a focus on spinal muscular atrophy (SMA), Scavina's innovative method offers new hope for the early diagnosis of this debilitating condition.
Latest Patents: Scavina holds a patent for a groundbreaking diagnostic method aimed at determining whether individuals are affected by spinal muscular atrophy. His patent outlines a procedure that evaluates the relative amounts of exon 5 of Neuronal Apoptosis Inhibitory Protein (NAIP) and exon 7 of both centromeric and telomeric Survival Motor Neuron (SMN) genes. The method employs PCR analysis using specific primers to amplify these genes, followed by enzyme digestion and electrophoresis to enable multiplex analysis. This approach not only enhances the diagnostic capabilities but also allows the identification of non-affected carriers, thereby expanding the understanding of SMA.
Career Highlights: Mena Scavina is associated with The Nemours Foundation, where he continues to develop and refine his diagnostic methods. His dedication to advancing medical diagnostics has positioned him as a key figure in the fight against spinal muscular atrophy.
Collaborations: Throughout his career, Mena has collaborated with notable professionals in the field. One of his prominent coworkers is Dr. Vicky L. Funanage, contributing valuable insights and expertise to enhance the research and applications of genetic diagnostics.
Conclusion: Mena Scavina's innovative contributions to the diagnosis of spinal muscular atrophy exemplify the vital role inventors play in the advancement of healthcare. His patented method not only aids in the detection of SMA but also empowers individuals by identifying carrier status, thus fostering informed medical decisions. With continued dedication and collaboration, Scavina is set to make an even greater impact in the realm of genetic diagnostics.